Loading
NASDAQHealthcareBiotechnology
Latest quote
$17.02
−$0.04 · -0.23%
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Latest quote
$17.02
−$0.04 · -0.23%
After-hours
$17.02
$0.00 · 0.00%
Sep 10, 5:27 PM ET
Regular session · ET · Market data may be delayed.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Day range
Current $17.02
52-week range
Current $17.02
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
87
Deep Value
Sentiment
58
Mixed
Risk
27
Moderate Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Day range
Current $17.02
52-week range
Current $17.02
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 107.46M USD | 64.38M USD | 57.42M USD | 51.35M USD | 55.31M USD |
| Cost of goods sold | 5.52M USD | 37.64M USD | 40.62M USD | 63.39M USD | 193.66M USD |
| Gross profit | 101.95M USD | 26.74M USD | 16.8M USD | −12.05M USD | −138.35M USD |
| Research and development | 37.41M USD | 38.05M USD | 46.34M USD | 70.07M USD | 201.55M USD |
| Selling, general, and administrative | 73.65M USD | 69.17M USD | 70.45M USD | 67.07M USD | 99.3M USD |
| Operating expenses | 115.2M USD | 73.69M USD | 72.84M USD | 79.91M USD | 119.44M USD |
| Interest income | — | 4.88M USD | 9.12M USD | 8.55M USD | 1.11M USD |
| Interest expense | 2.46M USD | 2.55M USD | 2.35M USD | 6.37M USD | 8.55M USD |
| Depreciation and amortization | 5.52M USD | 3.62M USD | 2M USD | 3.04M USD | 4.81M USD |
| Operating income | −13.25M USD | −46.95M USD | −56.04M USD | −91.96M USD | −257.78M USD |
| Net income | 105.9M USD | −56.42M USD | −55.19M USD | 872.13M USD | −199.43M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$17.00
0.12% downsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI21.85M0.00%2.3T USD0.03%$373.24-0.62%
iShares Russell 2000 ETFIWM17.74M0.02%80.51B USD0.19%$287.7-1.01%
Vanguard Extended Market ETFVXF7.36M0.01%93.7B USD0.05%$236.16-1.05%
iShares Biotechnology ETFIBB6.28M0.06%10.73B USD0.44%$202.64-1.39%
State Street SPDR S&P Pharmaceuticals ETFXPH6.15M1.00%616.33M USD0.35%$68.01-1.89%
iShares Russell 2000 Growth ETFIWO5.33M0.04%14.7B USD0.24%$365.67-1.42%
Vanguard Russell 2000 ETFVTWO3.82M0.02%17.4B USD0.06%$116.34-1.00%
Schwab U.S. Small-Cap ETFSCHA3.02M0.01%22.62B USD0.03%$33.65-1.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
